Study on sacituzumab govitecan in TNBC reveals diverse resistance mechanisms: some lesions resist TROP2 antibody, others the TOP1 payload. Senior author Aditya Bardia, MD, MPH, discusses implications for future treatments. bit.ly/4chCo3r #BCSM
0
0
0
98
0